201 related articles for article (PubMed ID: 19251953)
1. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
Magee G; Sharpe PC
J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed.
Mombelli G; Pazzucconi F; Bondioli A; Zanaboni A; Gaito S; Calabresi L; Sirtori CR
Cardiovasc Ther; 2010 Jun; 28(3):153-60. PubMed ID: 20337637
[TBL] [Abstract][Full Text] [Related]
3. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Maciejewski S; Hilleman D
Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
[TBL] [Abstract][Full Text] [Related]
5. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
7. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ;
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
9. Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
Unnikrishnan R; Das R; Jaydip R; Sudhakaran C; Mohan V
J Assoc Physicians India; 2009 Feb; 57():180-1. PubMed ID: 19582991
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
[TBL] [Abstract][Full Text] [Related]
11. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
[TBL] [Abstract][Full Text] [Related]
12. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
Zhu J; Ye P
Chin Med J (Engl); 2003 Jun; 116(6):840-3. PubMed ID: 12877791
[TBL] [Abstract][Full Text] [Related]
13. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
Yeganeh B; Moshtaghi-Kashanian GR; Declercq V; Moghadasian MH
J Nutr Biochem; 2005 Apr; 16(4):222-8. PubMed ID: 15808326
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
15. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
[TBL] [Abstract][Full Text] [Related]
17. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
18. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
[TBL] [Abstract][Full Text] [Related]
19. Iatrogenic severe depression of high-density lipoprotein cholesterol.
Mymin D; Dembinski T; Friesen MH
J Clin Pharmacol; 2009 Jul; 49(7):865-71. PubMed ID: 19403838
[TBL] [Abstract][Full Text] [Related]
20. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
Filippatos TD; Liberopoulos EN; Kostapanos M; Gazi IF; Papavasiliou EC; Kiortsis DN; Tselepis AD; Elisaf MS
Diabetes Obes Metab; 2008 Jun; 10(6):476-83. PubMed ID: 17459096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
